EADV-Kongress 2024: New Study said that Semaglutid improves the quality of life of patients with high blood pressure

A rapid study, which took place at the EADV Congress 2024, said the potential of semaglutide in the treatment of hidradenitis suppurativa (HS), a high and severe fever, in people with obesity.

AMSTERDAM, 24. September 2024 /PRNewswire/ — This is the first study to dissect the etiology of semaglutide in HS and provide a separate baseline for such work on this severe and serious illness.

HS considers the safety of 1 of 100 people, we are responsible for being a responsible risk manager. The Erkrankung is known through careful assessment and mental health, which can greatly improve the quality of life of the patients. The strength of defense in dealing with HS was the same as the development and success of the American economy, was an alternative and a very attractive German power.

In the study dating from the Zeitraum from June 2020 to March 2023, it is not possible that the healthy inheritance of 30 patients with an unreliable stage of HS is supported. The patients have semaglutide – a glucagon-like peptide (GLP)-1RA – in a dose of 0.8 mg only once a day for 8.2 months.

Die Ergebnisse has deutliche Verbesserungen bei den Patientenergebnissen in more Schlüsselbereichen.

If the patient notices the HS-Schübe, the patient will experience an episode of 8.5 weeks out of 12 weeks. If the quality of life was in German, it was a representation of the Dermatology Life Quality Index (DQLI) of 13/30 to 9/30 broader mirror.

The patient’s BMI decreased from 43.1 to 41.5, and his weight decreased from 117.7 kg to 111.6 kg, but a drop from the patient would be 10 kg or less in weight.

Further positive changes were observed at the unreported biochemical markers. The HbA1c value dropped from 39.3 to 36.6, was one of the controls on the blood sugar levels in the back, while the CRP value dropped from 7.8 to 6.9, was a smaller backward factor.

Doctor Daniel Lyonsthe leading researcher, explains: “Our point is that Semaglutid can provide significant benefits in the treatment of HS even in modest doses. When the role of medication in the financing of weight treatment develops, it is extremely exciting, if the high quality of HS-Schüben treatment can take place, this was the remarkable treatment of the patient’s quality of life.”

Dr. Lyons said, “The results are no longer appropriate and could be a major breakthrough in HS treatment. One of the advances that has been made is a larger randomized control trial, one of these big things that validates it.”

View original content: https://www.prnewswire.com/news-releases/eadv-kongress-2024-neue-studie-zeigt-dass-semaglutid-die-ergebnisse-bei-fettleibigen-patienten-mit-haufigen-hautkrankheiten-verbessert-302254057.html